Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.
第一作者:
Hiroyuki,Kashiwagi
第一单位:
Department of Surgery, Washington University School of Medicine, 660 S, Euclid Avenue, Campus Box 8109, St, Louis, MO 63110, USA. hawkinsw@wustl.edu
作者:
主题词
腺癌(Adenocarcinoma);动物(Animals);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);细胞凋亡(Apoptosis);细胞系, 肿瘤(Cell Line, Tumor);脱氧胞苷(Deoxycytidine);疾病模型, 动物(Disease Models, Animal);女(雌)性(Female);人类(Humans);分裂间期(Interphase);配体(Ligands);小鼠(Mice);小鼠, 近交C57BL(Mice, Inbred C57BL);紫杉酚(Paclitaxel);胰腺肿瘤(Pancreatic Neoplasms);受体, Σ(Receptors, sigma);存活率分析(Survival Analysis)
DOI
10.1186/1479-5876-7-24
PMID
19323815
发布时间
2022-12-07
- 浏览2
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文